SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses

Mostrar otras versiones (1)

BACKGROUND. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 110 million individuals and led to 2.5 million deaths worldwide. As more individuals are vaccinated, the clinical performance and utility of SARS-CoV-2 serology platforms needs to be evaluated. METHODS. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Suhandynata, Raymond T., Bevins, Nicholas J., Tran, Jenny T., Huang, Deli, Hoffman, Melissa A., Lund, Kyle, Kelner, Michael J., McLawhon, Ronald W., Gonias, Steven L., Nemazee, David, Fitzgerald, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987061/
https://www.ncbi.nlm.nih.gov/pubmed/33758902
http://dx.doi.org/10.1101/2021.03.10.21253299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7987061/
https://www.ncbi.nlm.nih.gov/pubmed/33758902
http://dx.doi.org/10.1101/2021.03.10.21253299

Ejemplares similares